selegiline has been researched along with morphine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Arnaldos, JD; Cremades, A; Milanés, MV; Vargas, ML | 1 |
| Cerza, RF | 1 |
| Demuth, M; Götz, ME; Koutsilieri, E; Riederer, P; Sauer, U; Sopper, S; ter Meulen, V | 1 |
| Ghosh, S; Grasing, K | 1 |
| Grasing, K; He, S; Li, N | 1 |
| Grasing, K; He, S | 2 |
| Chauhan, A; Chen, KC; Conant, K; Cutler, R; Gairola, C; Gartner, S; Haughey, N; Hauser, KF; Jie, C; Liu, Y; Mattson, MP; McArthur, JC; Nath, A; Pardo, C; Peng, X; Reid, R; Sacktor, N; Turchan-Cholewo, J | 1 |
| Charkhpour, M; Ghaderi, M; Habibi-asl, B; Hassanzadeh, K; Parvizpour, A; Shakhsi, M | 1 |
1 review(s) available for selegiline and morphine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
16 other study(ies) available for selegiline and morphine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Effect of selective monoamine oxidase inhibitors on the morphine-induced hypothermia in restrained rats.
Topics: Animals; Body Temperature; Clorgyline; Dose-Response Relationship, Drug; Drug Interactions; Female; Male; Monoamine Oxidase Inhibitors; Morphine; Naloxone; Phenethylamines; Rats; Rats, Inbred Strains; Selegiline | 1987 |
Beta-selective monoamine oxidase inhibitors and cardiac anesthesia.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Anesthetics, Inhalation; Anesthetics, Intravenous; Aortic Valve; Coronary Artery Bypass; Drug Interactions; Etomidate; Female; Heart Valve Prosthesis; Humans; Hydromorphone; Hypnotics and Sedatives; Lorazepam; Monoamine Oxidase Inhibitors; Morphine; Selegiline | 1995 |
Regulation of glutathione and cell toxicity following exposure to neurotropic substances and human immunodeficiency virus-1 in vitro.
Topics: AIDS Dementia Complex; Carrier Proteins; Cell Survival; Cells, Cultured; Cocaine; Disease Progression; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Glutathione; HIV-1; Humans; Macrophages; Membrane Glycoproteins; Membrane Transport Proteins; Morphine; Narcotics; Nerve Tissue Proteins; Oxidative Stress; Selegiline; Substance-Related Disorders; Tumor Cells, Cultured; Up-Regulation | 1997 |
Selegiline prevents long-term changes in dopamine efflux and stress immobility during the second and third weeks of abstinence following opiate withdrawal.
Topics: Animals; Dopamine; Male; Morphine; Rats; Rats, Wistar; Restraint, Physical; Selegiline; Stress, Physiological; Substance Withdrawal Syndrome | 1998 |
Selegiline modifies the extinction of responding following morphine self-administration, but does not alter cue-induced reinstatement, reacquisition of morphine reinforcement, or precipitated withdrawal.
Topics: Animals; Cues; Extinction, Psychological; Male; Morphine; Rats; Rats, Wistar; Reinforcement, Psychology; Selegiline; Self Administration; Substance Withdrawal Syndrome | 2005 |
Effects of high-dose selegiline on morphine reinforcement and precipitated withdrawal in dependent rats.
Topics: Acoustic Stimulation; Analgesics, Opioid; Animals; Conditioning, Operant; Cues; Dopamine; Eating; Male; Monoamine Oxidase Inhibitors; Morphine; Morphine Dependence; Motor Activity; Naloxone; Narcotic Antagonists; Photic Stimulation; Rats; Rats, Wistar; Reinforcement Schedule; Reinforcement, Psychology; Selegiline; Self Administration; Substance Withdrawal Syndrome | 2005 |
Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: protection by diosgenin and L-deprenyl.
Topics: Adult; AIDS Dementia Complex; Antioxidants; Apolipoprotein E4; Apolipoproteins E; Cells, Cultured; Coculture Techniques; Diosgenin; Gene Expression; Gene Products, tat; Genetic Predisposition to Disease; HIV; HIV Envelope Protein gp120; HIV Infections; Humans; Male; Membrane Potentials; Mitochondria; Morphine; Narcotics; Neurons; Neuroprotective Agents; Neurotoxins; Oligonucleotide Array Sequence Analysis; Oxidative Stress; Polymerase Chain Reaction; Reactive Oxygen Species; Selegiline; tat Gene Products, Human Immunodeficiency Virus; Viral Proteins | 2006 |
L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action.
Topics: Animals; Behavior, Animal; Body Weight; Central Nervous System Stimulants; Clorgyline; Conditioning, Operant; Extinction, Psychological; Indans; Male; Methamphetamine; Monoamine Oxidase Inhibitors; Morphine; Morphine Dependence; Rats; Rats, Wistar; Reinforcement, Psychology; Selegiline; Self Administration; Substance Withdrawal Syndrome | 2006 |
Repeated central administration of selegiline attenuated morphine physical dependence in rat.
Topics: Animals; Infusions, Intraventricular; Male; Morphine; Morphine Dependence; Naloxone; Rats; Rats, Sprague-Dawley; Rats, Wistar; Selegiline; Substance Withdrawal Syndrome; Substance-Related Disorders | 2013 |